Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will pr...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off the final day of the workweek with an overview of the biggest pre-market stock movers for Friday! Source: f11photo/Shutterstock.com A statement from Elon Musk, several earnings reports, and...
Calithera Biosciences (NASDAQ:CALA) stock plunges after Ladenburg analyst Aydin Huseynov lowered the price target to $1.50 from $3 and maintains a Buy rating on the shares after its Q1 results. The company is developing two recently in-licensed oncology assets simultaneously, but th...
Image source: The Motley Fool. Calithera Biosciences (NASDAQ: CALA) Q1 2022 Earnings Call May 10, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Calithera Biosciences (CALA) Q1 2022 Earnings Call Transcript
Calithera Biosciences, Inc. (CALA) Q1 2022 Earnings Conference Call May 10, 2022, 05:00 PM ET Company Participants Susan Molineaux - Founder, President & CEO Stephanie Wong - CFO Emil Kuriakose - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Nick Abbott -...
Calithera Biosciences press release (NASDAQ:CALA): Q1 GAAP EPS of -$0.18 in-line. Net loss for the three months ended March 31, 2022 was $13.8 million. Cash and cash equivalents totaled $44.7 million at March 31, 2022, which Calithera expects, together with proceeds from its public offering, ...
-- Conference Call and Webcast Scheduled for 2:00 p.m. PT / 5:00 p.m. ET on Tuesday, May 10, 2022 -- SOUTH SAN FRANCISCO, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced ...
SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company’s first quarter 2022 financial results will be released on Tuesday, May 10, 2022....
3 Under $1 Penny Stocks to Watch in May 2022 Finding the best penny stocks to buy under $1 is all about doing your due diligence and finding the most promising companies with good prospects for future growth. Because penny stocks are so speculative, understanding exactly what is goi...
Findings presented today at AACR Annual Meeting detail Calithera discovery of VPS4A inhibitors and their potential as a therapeutic approach in numerous solid tumor cancers VPS4A and VPS4B are gene paralogs that show strong synthetic lethal interaction SOUTH SAN FRANCISCO,...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
NASDAQ Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...